Capable of simultaneously degrading key proteins across multiple pathways—including HER2, EGFR, and Akt—thereby broadly suppressing resistance mechanisms; effectively eliminates both tumor cells and cancer stem-like populations to inhibit drug-resistant tumor growth. Here, ERBB2 is linked to cancer.